DexCom Inc Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 108 trades in DexCom Inc (NASDAQ: DXCM) since 2014, across 14 members, worth an estimated $2.9M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 56 buys against 52 sells, a modestly buy-led skew, with Democratic members responsible for 46% of the trades and Republican members 54%. The most recent disclosure shown was filed May 2026, and Michael T. McCaul has filed the most DXCM transactions among those shown, with 11. Other recent filers include Tina Smith, Ro Khanna, and John Boozman. One notable disclosed move was a purchase by Michael T. McCaul on July 30, 2025, down 18.3% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the DexCom Inc (DXCM) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
DexCom congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | |
|---|---|---|---|---|---|---|---|
 Tina Smith Senate | May 10, 2026 | May 7, 2026 | 3 days | SELL |  $100,001 - $250,000 | +19.47% | |
Tina Smith Senate | May 10, 2026 | Apr 29, 2026 | 11 days | SELL | $100,001 - $250,000 | +26.42% | |
 Ro Khanna House | Apr 7, 2026 | Mar 30, 2026 | 8 days | SELL | $1,001 - $15,000 | +17.56% | |
Ro Khanna House | Apr 7, 2026 | Mar 23, 2026 | 15 days | SELL | $1,001 - $15,000 | +10.36% | |
Ro Khanna House | Mar 9, 2026 | Feb 17, 2026 | 20 days | BUY | $1,001 - $15,000 | +3.32% | |
Ro Khanna House | Mar 9, 2026 | Feb 5, 2026 | 32 days | SELL | $1,001 - $15,000 | +4.12% | |
 Michael T. McCaul House | Mar 10, 2026 | Feb 4, 2026 | 34 days | SELL | $1,001 - $15,000 | +2.75% | |
Ro Khanna House | Feb 6, 2026 | Jan 29, 2026 | 8 days | BUY | $1,001 - $15,000 | -1.66% | |
 John Boozman Senate | Feb 15, 2026 | Jan 26, 2026 | 20 days | BUY | $1,001 - $15,000 | -0.78% | |
Michael T. McCaul House | Nov 10, 2025 | Oct 27, 2025 | 14 days | SELL | $15,001 - $50,000 | +3.03% |
DexCom (DXCM) congressional trading FAQ
Can members of Congress legally trade DexCom (DXCM) stock?
Yes. Members of Congress are permitted to trade individual stocks, including DexCom (DXCM), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; it does not imply any trade was improper.
Are congressional DexCom (DXCM) trades public?
Yes. Every congressional trade in DexCom (DXCM) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded DexCom (DXCM)?
Members of Congress have disclosed 108 trades in DexCom (DXCM) worth $2.9M across 14 members, according to public STOCK Act filings.
Which members of Congress have traded DexCom (DXCM)?
Recent and active filers of DexCom (DXCM) disclosures include Michael T. McCaul, Ro Khanna, Tina Smith. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade DexCom (DXCM) more?
Across disclosed DexCom (DXCM) trades, 46% were by Democrats and 54% by Republicans, led by Republicans (54%).
What is the most recent congressional DexCom (DXCM) trade?
The most recent disclosed DexCom (DXCM) trade was a sale by Tina Smith, filed May 9, 2026.
Browse all stocks Congress tradesCongressional trading overviewDexCom (DXCM) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.